Nov 13 2023Reviewed by Lily Ramsey, LLM Today, UNITE4TB, an international public-private partnership striving to fast-track the development of innovative Tuberculosis treatments, announced the start of its phase 2B/C clinical trial program with the first participant enrolled at its trial site in Cape Town, South Africa.
For people affected by TB, the most important outcome is rapid access to better regimens of shorter treatment duration and with fewer side effects. UNITE4TB is engaging with key societal stakeholders to ensure that its novel regimens will be made available as efficiently as possible. UNITE4TB’s explorative regimens have been constructed by combining the novel compounds GSK656 and BTZ-043 with the most recently licensed drug classes: diarylquinoline and nitroimidazoles . Apart from DECISION, a BTZ-043 dose evaluation in combination study, the UNITE4TB trial program includes PARADIGM4TB, a phase 2B/C platform trial to evaluate multiple regimens and durations of treatment in Pulmonary Tuberculosis.
The South African trial site, part of the clinical research institute TASK, where the first participant in the UNITE4TB trial program has been enrolled, is one of several selected for the project. The sites were chosen based on TB prevalence. Other high-burden countries on the trial site list include Tanzania, Uganda, Vietnam, and the Philippines.